Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Construction in Progress (2021 - 2023)

Historic Construction in Progress for Pharmaceuticals (CASI) over the last 3 years, with Q4 2023 value amounting to $23000.0.

  • Pharmaceuticals' Construction in Progress fell 9959.85% to $23000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $23000.0, marking a year-over-year decrease of 9959.85%. This contributed to the annual value of $23000.0 for FY2023, which is 9959.85% down from last year.
  • Pharmaceuticals' Construction in Progress amounted to $23000.0 in Q4 2023, which was down 9959.85% from $5.7 million recorded in Q4 2022.
  • Pharmaceuticals' 5-year Construction in Progress high stood at $12.1 million for Q4 2021, and its period low was $23000.0 during Q4 2023.
  • Moreover, its 3-year median value for Construction in Progress was $5.7 million (2022), whereas its average is $5.9 million.
  • In the last 5 years, Pharmaceuticals' Construction in Progress crashed by 5264.16% in 2022 and then tumbled by 9959.85% in 2023.
  • Quarter analysis of 3 years shows Pharmaceuticals' Construction in Progress stood at $12.1 million in 2021, then tumbled by 52.64% to $5.7 million in 2022, then plummeted by 99.6% to $23000.0 in 2023.
  • Its Construction in Progress was $23000.0 in Q4 2023, compared to $5.7 million in Q4 2022 and $12.1 million in Q4 2021.